Active Pipeline Summary

90 programs
available for collaboration

Ainnocence's AI platform supports a discovery and lead-stage portfolio spanning antibodies, multi-specific biologics, ADCs, and GPCR antibody/nanobody programs.

90
Programs
4
Modalities
70+
Targets
mAb / VHH
Bispecific / Trispecific
ADC
GPCR Ab / Nanobody
Program
Targets
DiscoveryLead IDLead Opt.Preclinical
Autoimmune / Anti-inflammatory · 27 programs

mAb programs · 13 targets

mAb / VHH

CD122, TL1A, IL-23 p19, A4B7, BAFFR, FcRn, TMEM219, TSLP, IL-33, IL-13, IL-25, IL-36R, IL-18

Bispecific programs · 12

Bi / Tri-specific

CD122xTL1A, A4B7xIL-23, TSLPxIL-13, IL-25xIL-13, TMEM219xTL1A, IL-23xTL1A, BAFFRxTL1A and additional combinations

Trispecific antibodies · 2

Bi / Tri-specific

IL-33xTSLPxIL-13; TSLPxIL-25xIL-13

Oncology · 28 programs

mAb programs · 13 targets

mAb / VHH

PD-L1, TROP2, VEGF, GPNMB, B7H3, HHLA2, EPHA5, DLK1, MELTF, MUC16, DLL3, CD200, IGF2

Bispecific programs · 6

Bi / Tri-specific

PDL1xHHLA2, PDL1xEPHA5, DLK1xEPHA5, PDL1xDLK1, MELTFxVEGF, DLK1xVEGF

Trispecific antibody · 1

Bi / Tri-specific

PDL1xTROP2xVEGF

Antibody-drug conjugates · 8

ADC

PDL1xTROP2, TROP2xVEGF, PDL1xB7H3, PDL1xGPNMB, MELTF, DLK1xVEGF, PDL1xEPHA5, PDL1xDLK1

Metabolic

ActRII A/B programs · 2 targets *

mAb / VHH

ActRII A/B, Myostatin - lead candidates advancing toward animal studies

CNS / Neuroregeneration & Addiction

mAb programs · 4 targets *

mAb / VHH

CD98 (BBB shuttle, animal discussions), Nogo-A, HMGB1, GDF15

GPCR Antibody & Nanobody Program

Ab / Nanobody · 29 targets

Ab / Nanobody

GLP1R, GIPR, GCGR, CCR8, CCR5, CCR2, CXCR2-6, S1PR1, ADORA2A, MC4R, C5AR1, PAR2/4 and more

* Lead candidates advancing to animal studies. Stages shown are discovery through preclinical; no clinical-stage programs are represented on this summary.

Platform Foundation

AINN-P1 powers sequence-first collaboration.

AINN-P1 is a 157M-parameter protein foundation model built for sequence-to-function prediction without requiring 3D modeling. Specialized downstream models support binding, immunogenicity, stability, and epitope mapping across mAb, bispecific, ADC, VHH, and scFv programs.

Partnering Focus

  • Portfolio licensing or target-specific collaboration
  • Lead generation and optimization partnerships
  • AI-enabled antibody, ADC, VHH, and GPCR programs
  • 20+ patent portfolio supporting platform and modality work
Discuss Collaboration